Tech Company Financing Transactions
Argos Therapeutics Funding Round
Argos Therapeutics closed a $5 million funding round on 4/20/2007. Investors included Oxford Finance and Silicon Valley Bank.
Transaction Overview
Company Name
Announced On
4/20/2007
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The financing will be used primarily to fund the Company´s three ongoing clinical trials in renal cell carcinoma (Phase 2), chronic lymphocytic leukemia (Phase 1/2) and HIV (Phase 1), utilizing its personalized RNA-loaded dendritic cell-based immunotherapy ("Arcelis") technology for cancer and HIV.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
4233 Technology Dr.
Durham, NC 27704
USA
Durham, NC 27704
USA
Phone
Website
Email Address
Overview
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Abbey
Chief Financial Officer
Richard Katz
Chief Scientific Officer
Charles Nicolette
VP - Finance
Lori Harrelson
Browse more venture capital transactions:
Prev: 4/20/2007: Fintura venture capital transaction
Next: 4/20/2007: SurgRx venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs